Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2007

Trellis Bioscience and PDL BioPharma Partner to Discover Novel Antibodies

  • PDL BioPharma and Trellis Bioscience entered into a collaboration in which Trellis’ CellSpot™ technology will be used to discover monoclonal antibodies directed against a PDL antigen.

    “There are many antigens to which specific, high-affinity monoclonal antibodies have been difficult or impossible to generate,” stated Nolan H. Sigal, M.D., Ph.D., president of Trellis Bioscience. “Antibody CellSpot is a novel discovery platform that greatly enhances the odds of finding and retrieving the cells that are making desired antibodies but which are escaping detection through conventional discovery techniques due to their rarity.”

    Under the terms of the agreement, Trellis will use Antibody CellSpot to screen large populations of antibody-producing cells developed by the parties using a variety of immunization strategies. Trellis will select and deliver hybridomas to PDL BioPharma, which will conduct further research and development on the antibodies. PDL BioPharma will develop and commercialize any products discovered during the research collaboration, and Trellis will receive an upfront fee, milestone payments, and royalties on products discovered in the collaboration.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »